Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 12/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 12/20 | 0.39 |
| ▸ | KAT6B | Q8WYB5 | 8/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 5/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31691304 | 0.89 | KAT7 (0.38) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691277 | 0.86 | KAT7 (0.38) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691261 | 0.86 | KAT7 (0.43) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691361 | 0.86 | KAT7 (0.36) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31172522 | 0.84 | KAT7 (0.52) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691325 | 0.84 | KAT7 (0.34) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691480 | 0.83 | KAT7 (0.42) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691398 | 0.83 | KAT7 (0.43) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691319 | 0.82 | KAT7 (0.44) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691344 | 0.81 | KAT7 (0.42) | KAT7KAT6AKAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304535-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-02 | — | — | US | disclosed |
| WO-2025201504-A1 | KAT6 INHIBITORS | BEIGENE (SUZHOU) CO., LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304535-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT2A | KAT7 4/4885KAT6A 1/4885KAT6B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.